Antiangiotide

安替安吉肽

Report date: 2025/10/20 14:43:24
NME

Base Information

Drug NameAntiangiotide
Drug Alias NameHM-3IIM-3
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInner Mongolia Tianqi Pharmaceutical Group Co LtdChina Pharmaceutical University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInner Mongolia Tianqi Pharmaceutical Group Co LtdBeijing Science Sun Pharmaceutical Co LtdChina Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A